The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls

Wu, Xiaoli; Huang, Zhichao; Wu, Renrong; Zhong, Zhaohui; Wei, Qian; Wang, Houliang; Diao, Feiyang; Wang, Jihui; Zheng, Liang; Zhao, Jingping; Zhang, Jinbei

doi:10.1016/j.schres.2013.07.051

Cited by 73 publications

(36 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study we also found that drug-naïve schizophrenia patients had higher fasting plasma insulin and C-peptide levels and lower fasting plasma HDL-C and aPOA1 levels and were more insulin resistant compared with healthy controls. Given the results of both the present study and our previous study,39 we can conclude that the risk of glucose and lipid metabolism disturbances among Chinese patients with schizophrenia may be associated with not only schizophrenia itself but antipsychotic drugs as well.…”

Section: Discussionsupporting

confidence: 74%

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

Wu¹,

Huang²,

Han³

et al. 2014

NDT

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough many studies have reported that glucose and lipid metabolism disorders are a significant side effect associated with the use of antipsychotic drugs, the characteristics of glucose and lipid metabolism disorders in patients with schizophrenia who are taking antipsychotic drugs remain poorly understood, and the possible effects that antipsychotic discontinuation may have on glucose and lipid metabolism remain unclear.MethodsThe sample consisted of 131 Chinese patients with schizophrenia, including 70 first-episode, drug-naïve patients; 33 patients who had received continuous antipsychotic drug treatment for ≥1 year prior to the beginning of the study; and 28 patients who had discontinued antipsychotic drug treatment for ≥3 months prior to the beginning of study. We compared the glucose and lipid metabolic parameter levels among the three groups of patients with schizophrenia. All assessments were performed upon hospital admission.ResultsThe characteristics of glucose and lipid metabolism disorders in Chinese patients with schizophrenia who are taking antipsychotic drugs included significant augmentation of the body mass index and waist circumference, significantly higher levels of fasting plasma insulin and insulin resistance, and significantly lower plasma high-density lipoprotein cholesterol levels. Antipsychotic discontinuation appeared to not significantly improve any plasma glucose and lipid metabolic parameter levels.ConclusionThe results suggest that antipsychotic drugs aggravate glucose and lipid metabolism disorders and that antipsychotic discontinuation is generally not associated with improvements in the parameters that indicate glucose and lipid metabolism disorders in Chinese patients with schizophrenia.

show abstract

Section: Discussionsupporting

confidence: 74%

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

Wu¹,

Huang²,

Han³

et al. 2014

NDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Polymorphisms in the MTHFR gene might also predict the development of metabolic side effects associated with second-generation antipsychotics (Misiak et al 2013). In addition, extensive evidence indicates that the prevalence of lipid and glucose metabolism disturbances is significantly higher in first-episode and drug-naïve schizophrenia patients in comparison with healthy controls (Chen et al 2013; Wu et al 2013; Cai et al 2012; Spelman et al 2007; Ryan et al 2003; McEvoy et al 2013). These findings point to the hypothesis that schizophrenia is in itself associated with metabolic deregulation.…”

Section: Introductionmentioning

confidence: 99%

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

et al. 2014

View full text Add to dashboard Cite

Accumulating evidence indicates that elevated homocysteine (Hcy) level occurs in first-episode schizophrenia (FES) patients. We included 56 FES patients and 53 healthy controls (HC). Plasma level of Hcy was significantly higher in FES patients than HC (p = 0.044). In addition, plasma levels of high-density lipoproteins (HDL) and folate were significantly lower in FES than in HC (p < 0.001). Positive family history of schizophrenia was associated with lower plasma HDL (p = 0.041) and vitamin B12 (p = 0.017), as well as higher level of Hcy (p = 0.017). Patients with FES, who abused cannabis, had higher levels of Hcy (p = 0.017), as well as lower levels of vitamin B12 (p = 0.017) and HDL (p = 0.041). Plasma Hcy negatively correlated with duration of untreated psychosis (r = −0.272, p = 0.042). There was a positive correlation between Hcy level and the severity of negative symptoms (r = 0.363, p = 0.006) and general psychopathology (r = 0.349, p = 0.008) assessed using Positive and Negative Syndrome Scale (PANSS). Vitamin B12 level was negatively associated with the severity of negative symptoms (r = −0.406, p = 0.002), while folate level negatively correlated with general psychopathology score (r = −0.365, p = 0.006) in PANSS. These results indicate that the severity of one-carbon metabolism alterations and HDL deficiency might be associated with family history of schizophrenia and cannabis abuse. Lower vitamin B12 and folate along with elevated Hcy may influence the severity of FES psychopathology.

show abstract

“…Kosten@bcm.edu & Xiang-Yang Zhang xiang.y.zhang@uth.tmc.edu controls [13]. This suggests that lipid metabolism is abnormal in schizophrenic patients before the commencement of antipsychotic drug treatment.…”

Section: And Thomas R Kostenmentioning

confidence: 99%

Smoking and Serum Lipid Profiles in Schizophrenia

Tan

et al. 2016

Neurosci. Bull.

View full text Add to dashboard Cite

Schizophrenia is associated with a high prevalence of cigarette-smoking and abnormal lipid profiles. The purpose of this study was to determine whether the profiles differ between schizophrenic smokers and non-smokers and whether the lipid profiles are related to psychopathological symptoms. Serum lipid profiles were measured in 130 male inpatients with DSM-IV-defined schizophrenia: 104 smokers and 26 non-smokers. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Our results showed that positive PANSS symptoms were fewer in smokers than in non-smokers, while the negative symptoms were fewer in those who smoked more cigarettes. Total protein and globulin levels were significantly lower in the smokers than in the non-smokers. However, there was no significant difference in total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol, apolipoprotein A1, or apolipoprotein B between the smokers and non-smokers. However, the PANSS positive subscale had a significant negative correlation with the HDL-c levels (a protective factor) in the smokers but not in the non-smokers. Our findings suggest that schizophrenic patients who smoke have fewer psychotic symptoms, but contrary to expectation, smoking does not alter lipid profile levels.

show abstract

The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls

Cited by 73 publications

References 35 publications

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Smoking and Serum Lipid Profiles in Schizophrenia

Contact Info

Product

Resources

About

The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls

Cited by 73 publications

References 35 publications

The comparison of glucose and lipid metabolism parameters in drug-na&iuml;ve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

The comparison of glucose and lipid metabolism parameters in drug-na&iuml;ve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Smoking and Serum Lipid Profiles in Schizophrenia

Contact Info

Product

Resources

About

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia